Stifel Nicolaus Believes Argenx Se (ARGX) Still Has Room to Grow

Stifel Nicolaus analyst Derek Archila maintained a Buy rating on Argenx Se (ARGX) today. The company’s shares opened today at $111.32, close to its 52-week high of $114.84.

Archila wrote:

“We believe ARGX’s collaboration agreement with Halozyme Therapeutics (HALO, $16.12, Not Covered) is an important development for the company and the FcRn competitive landscape. Having already validated a small volume subcutaneous dose of efgartigimod, ARGX remains in the lead on this initiative, and we believe the exclusive license signed with HALO for its validated ENHANZE drug delivery technology not only could offer even more dosing convenience for patients, but, based on our understanding from communicating with ARGX, it also prevents other FcRn competitors from collaborating with HALO on a subcutaneous dosing strategy.”

According to, Archila has currently no stars on a ranking scale of 0-5 stars, with an average return of -7.4% and a 34.7% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Rhythm Pharmaceuticals Inc, and Aimmune Therapeutics.

Currently, the analyst consensus on Argenx Se is a Strong Buy with an average price target of $143.60, representing a 29.0% upside. In a report released today, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $114.84 and a one-year low of $63.81. Currently, Argenx Se has an average volume of 230K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

argenx SE is a clinical-stage biotechnology company, which engages in the research and development of human monoclonal antibodies for the treatment of cancer and oncological, autoimmune, and inflammatory diseases. Its products include ARGX-113 for severe autoimmune diseases and ARGX-110 for T-cell lymphoma and acute myeloid leukemia.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts